Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 92
- Registration Number
- NCT05355818
- Locations
- 🇬🇧
LEO Pharma investigational site, Walsall, United Kingdom
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 35
- Registration Number
- NCT05332366
- Locations
- 🇺🇸
LEO Investigational Site, Burlington, Massachusetts, United States
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 513
- Registration Number
- NCT05259722
- Locations
- 🇪🇸
LEO Pharma investigational site, Pontevedra, Spain
🇬🇧LEO Pharma Investigational Site, Nottingham, United Kingdom
Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 136
- Registration Number
- NCT05194540
- Locations
- 🇺🇸
LEO Pharma Investigational Site, Hialeah, Florida, United States
🇺🇸LEO Pharma Investigator, Webster, Texas, United States
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT05099133
- Locations
- 🇺🇸
LEO Investigational Site, Los Angeles, California, United States
A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT05050279
- Locations
- 🇬🇧
Labcorp Clinical Research Unit (CRU) Ltd, Springfield House, Hyde Street,, Leeds, United Kingdom
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 801
- Registration Number
- NCT04949841
- Locations
- 🇬🇧
Leo Investigational Site, London, United Kingdom
🇩🇰LEO investigational site, Copenhagen, Denmark
🇵🇱LEO Pharma Investigational Site, Rzeszów, Poland
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 58
- Registration Number
- NCT04922021
- Locations
- 🇵🇱
LEO Pharma nvestigational Site, Rzeszów, Poland
🇵🇱LEO Pharma Investigational Site, Wrocław, Poland
A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 108
- Registration Number
- NCT04883333
- Locations
- 🇳🇱
LEO Pharma Investigational Site, Groningen, NZ, Netherlands
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 473
- Registration Number
- NCT04872101
- Locations
- 🇪🇸
LEO Investigational Site, Sevilla, Spain
🇩🇪LEO Invesitgational Site, Hannover, Germany